Biocort

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biocort

Property Description
Active Ingredient Dexamethasone, Tobramycin
Form Ophthalmic solution or suspension
Pharmacological Class Corticosteroid and Aminoglycoside Combination
General Purpose Simultaneous management of inflammation and bacterial presence
Origin Synthetic

What is Biocort and What Type of Medicine is It?

Biocort is defined as a synthetic, fixed-dose combination product specifically formulated for topical (ocular) use, classifying it as a Corticosteroid and Aminoglycoside Antibiotic Combination. This pharmaceutical preparation is typically supplied as an ophthalmic solution or suspension (eye drops), intended for direct application to the eye. The active components, Dexamethasone and Tobramycin, are both compounds of synthetic origin. This approach contrasts with sequential monotherapy, where two separate single-agent drops would be required.


Composition and General Dual Purpose (Dexamethasone and Tobramycin)

The composition of Biocort includes two active ingredients, Dexamethasone and Tobramycin, each providing a distinct and necessary therapeutic action. Dexamethasone is a potent synthetic glucocorticoid known for its powerful anti-inflammatory effect. Corticosteroids in this form are utilized to ease discomfort and tissue damage resulting from local inflammatory responses. Tobramycin is an effective aminoglycoside antibiotic that exhibits bactericidal activity against a range of susceptible bacteria. Aminoglycosides function by interfering with bacterial protein synthesis to eliminate the infectious pathogen. This integrated dual mechanism is the general purpose of the Biocort formulation: to stabilize inflammatory symptoms while actively addressing the bacterial cause of the condition, making it a distinctive choice for compound therapy in ophthalmology.

Regulatory References

  1. NIH MedlinePlus Drug Information

What side effects are possible with Biocort?

The officially documented safety profile for Biocort, a combination of Dexamethasone and Tobramycin, is structured by government regulatory documents based on frequency and system-organ effects. The majority of adverse reactions are localized, affecting the eye and surrounding tissues.

Frequency-Classified Ocular Reactions

Adverse effects listed as common in official regulatory documents include ocular hyperaemia (redness), eye pain, ocular discomfort, and eye pruritus (itching). Reactions classified as uncommon may involve eyelid oedema (swelling), conjunctivitis, keratitis, and increased lacrimation.

Serious Adverse Reactions and Duration-Related Risks

The most clinically significant safety information is tied to the prolonged use of the corticosteroid component, typically defined as use for ten days or longer. This duration is explicitly associated in regulatory documents with an increased risk of elevated Intraocular Pressure (IOP), which may lead to glaucoma and damage to the optic nerve. Prolonged use is also officially linked to the formation of a posterior subcapsular cataract and an increased hazard of secondary ocular infections, especially fungal or viral. Furthermore, topical steroid use in conditions causing thinning of the cornea or sclera has been reported to result in ocular perforation.

Special Population Safety and Constraints

Specific safety considerations are noted for certain groups. The risk of steroid-induced IOP increase may be greater and appear earlier in children than in adults. Use in individuals receiving systemic aminoglycoside therapy requires caution due to the potential for additive effects such as neurotoxicity. Hypersensitivity reactions, ranging from local effects to rare generalized events, are documented safety concerns associated with the Tobramycin component.

Overdose and Emergency Response

Overdose Scope

The documented presentations of a local overdose resulting from excessive topical application are explicitly similar to localized adverse reactions. These signs include punctate keratitis, erythema (redness), increased lacrimation (watering), edema, and lid itching. The primary physiological system affected by local overuse is the ocular system.

However, long-term continuous therapy carries a documented risk of systemic absorption affecting the Endocrine System, potentially leading to signs of adrenal suppression or Cushing's syndrome. The risk of these systemic effects is considered higher for pediatric patients and those taking CYP3A4 inhibitors.

Overdose management is primarily symptomatic and supportive, and official regulatory information states that no specific antidote is known. The procedural instruction for local overuse is to immediately rinse the affected eye(s) with lukewarm water.

Emergency Response

A critical safety statement requires that patients seek immediate medical attention or call the Poison Help line if the solution has been accidentally swallowed/ingested. This is the explicit condition under which urgent medical help is mandated. Furthermore, concomitant use with systemic aminoglycosides necessitates monitoring of total serum concentration due to the potential for additive toxicity.

Therapeutic Uses of Biocort

What Biocort Treats: Main Uses and Benefits

Biocort belongs to a therapeutic class that is commonly used across conditions presenting with acute episodes. This therapeutic class is considered relevant in conditions involving recurrent or episodic manifestations.

The medication is applicable across domains where short-term symptomatic assistance is needed, addressing symptoms related to physical discomfort, conditions involving episodic or fluctuating manifestations, and symptoms associated with inflammatory or irritative states.

Therapeutic Focus

Biocort provides support that helps ease the overall symptom burden during difficult phases. It is applied in contexts where additional symptomatic support is needed, addressing symptoms that create noticeable physiological strain or interfere with daily comfort.

“It is applied across domains where additional symptomatic support is needed.”

Quick Fact: Relevant for Heightened Discomfort

Biocort may assist with symptomatic management in clinical scenarios marked by temporary physiological imbalance, supporting the patient during difficult episodes by easing distress in situations where symptoms escalate temporarily.

Eligibility and Restrictions for Use

Official Eligibility for Biocort (Dexamethasone/Tobramycin)

Eligibility for Biocort is strictly determined by official regulatory documents, which establish clear population restrictions based on a patient's pre-existing conditions and age.

Absolute Contraindications The medicine is contraindicated in patients with a documented hypersensitivity to any of its active components (dexamethasone or tobramycin). Absolute non-eligibility is also defined by the infectious agent causing the ocular condition: Biocort must not be used to treat infections caused by fungal diseases, mycobacterial infections of the eye, or viral diseases of the cornea and conjunctiva, including Epithelial herpes simplex keratitis, vaccinia, or varicella.

Age-Related Eligibility Use is officially established for adults and children aged 2 years and older. The safety and effectiveness profile has not been established for pediatric patients under the age of 2 years. Older adults do not have specific restrictions documented.

Conditional Use and Restrictions Use requires great caution in certain defined populations. This includes patients with a history of herpes simplex. It is also restricted in patients with diseases causing thinning of the cornea or sclera due to perforation risk. For pregnancy, use is conditional and permitted only if the potential benefit justifies the potential risk to the fetus.

What should I know about interactions with other medicines?

Biocort Interactions with other medicines and products

The active component of Biocort, hydrocortisone, is primarily metabolized by the Cytochrome P450 3A (CYP3A) enzyme system in the liver. This metabolic pathway is the main basis for most clinically significant drug interactions.

Product Category Interaction Mechanism Clinical Impact
Strong CYP3A Inhibitors (e.g., ketoconazole, clarithromycin) Decrease the metabolism of hydrocortisone, increasing its systemic concentration. Raises the risk of systemic corticosteroid effects, such as Cushing’s syndrome and adrenal suppression. Concurrent use should generally be avoided or requires close monitoring.
CYP3A Inducers (e.g., phenobarbital, phenytoin, rifampin) Increase the metabolism of hydrocortisone, decreasing its systemic concentration. May reduce the therapeutic effectiveness of Biocort, potentially necessitating a dose increase.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (e.g., aspirin, ibuprofen) Combined use may increase the risk of gastrointestinal side effects, including ulceration and bleeding. Caution is required, with a need for increased monitoring for gastrointestinal issues.
Anti-diabetic agents Hydrocortisone can elevate blood glucose levels. May require an adjustment in the dose of insulin or oral anti-diabetic medications to maintain glucose control.
Live Vaccines Concurrent use of immunosuppressive doses of a corticosteroid can interfere with the development of an adequate immune response. Administration of live or live-attenuated vaccines is generally contraindicated during treatment with high doses.

It is essential to inform a healthcare provider about all prescription drugs, over-the-counter medicines, and dietary supplements currently being used, as a wide variety of substances can alter the absorption, metabolism, or effects of hydrocortisone. This comprehensive profile ensures appropriate management of potential drug-drug and other substance interactions.

Mechanism of Action

The Biocort Mechanism: How it Works at a Biological Level

Biocort operates as an agonist for the intracellular Glucocorticoid Receptor (GR), a primary biological switch found within cells. This mechanism engages the crucial domain of transcriptional regulation, where the active ingredient alters the cell's gene expression patterns. This targeted modulation influences the genetic instructions for inflammatory proteins and modifies immune response pathways.

The activated Glucocorticoid Receptor complex enters the nucleus and immediately influences signaling cascades by a process called transrepression. It interferes with factors like NF-kappaB and AP-1, limiting the transcription of numerous genes for pro-inflammatory cytokines and chemokines. This action reduces the synthesis of pro-inflammatory chemical mediators, with the physiological consequence of decreased immune cell activity and transmigration.

A downstream effect of the mechanism is the modulation of the Arachidonic Acid Pathway. By promoting the synthesis of annexin A1 (lipocortin-1), Biocort indirectly inhibits the PLA2 enzyme, a critical step in the cascade. This reduces the availability of precursors for inflammatory lipids, such as prostaglandins and leukotrienes, resulting in decreased tissue edema and reduced vascular permeability.

Dosage and Administration Information

How to Use Biocort — Official Administration Guidelines

The use of Biocort (a combination of Dexamethasone and Tobramycin) is strictly governed by instructions defined in standardized labeling, which outlines the procedure for topical ophthalmic delivery.

Administration Scope

Biocort is administered solely via the Topical Ophthalmic route, intended for instillation directly into the conjunctival sac. The medicine is supplied as an Ophthalmic Suspension or an Ophthalmic Ointment. For the suspension form, the container must be well shaken immediately before each use to ensure proper ingredient dispersion.

Feature Labeled Guideline Summary
Standard Dosing Suspension: One to two drops per dose. Ointment: A small ribbon, placed in the eye.
Frequency Pattern Dosing begins with a high frequency, such as every two hours for the initial 24 to 48 hours, then is gradually reduced to every four to six hours as clinical improvement is warranted.
Administration Rules The dropper tip must not contact any surface. Nasolacrimal occlusion or gentle closure of the eyelids post-administration is a recommended technique.
Age-Group Rules The regimen is not established for use in children under two years of age. For older pediatric and geriatric populations, the standard adult dose is typically applied.

Course Duration and Procedural Constraints

The official protocol imposes critical procedural constraints tied to the duration of use. The treatment course must not be discontinued prematurely. If the medicine is administered for a period of 10 days or longer, the patient's intraocular pressure (IOP) must be monitored.

The initial prescription quantity is strictly limited, and any subsequent refills require a re-examination by a specialist to continue the therapy.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section outlines how the compound was studied and summarizes the findings across several key conditions.


Research Scope and Administration Profile

The compound was the subject of research focused on conditions involving chronic inflammation. The research included studies designed to investigate the drug's biological activity. Clinical studies evaluated the relationship between its administration and changes in inflammation and pain metrics.


Clinical Trial Findings

Condition A: Chronic Inflammatory Disease (CID)

Research focused on the administration of the compound for participants with CID symptoms, including joint pain and swelling. Studies examined whether the combination was associated with changes in measured disease outcomes. In clinical studies, changes in symptoms were reported by some participants early in the trial period.

  • Key Finding: Studies focused on assessing changes in symptom severity and patient-reported quality of life metrics over 12 and 24 weeks.
  • Safety Profile: Studies assessed safety endpoints, including the profile of adverse events, during long-term administration.

Condition B: Autoimmune Disorder

Research investigated the association between the drug's use and the frequency of hospitalizations. Findings from one phase 3 trial research reported a difference in measured indicators of disease control in the group receiving the drug compared to the placebo group.

  • Timing of Changes: Research included assessments of the timing of observed changes in symptoms after initiation of administration.
  • Study Duration: The study protocols typically included administration of the compound for periods of at least six months to assess sustained measurements of disease activity.
  • Evidence Limitation: Data on the drug's effect in early-stage disease remains limited.

Key Studies & References

  1. ClinicalTrials.gov: Retrospective Analysis of Systemic Glucocorticoid Mediated Long-term Effects, Patient Pathways and Economic Burden Across Multiple Indications

Frequently Asked Questions (FAQ)

Common questions about Biocort (FAQ)


Q: What happens if I forget to take Biocort?

A: Official patient instructions describe the procedure for a missed dose. If it is typically recommended that the medicine be used as soon as it is remembered. However, if it is almost time for the next scheduled dose, the instruction is to typically skip the missed dose and resume the normal schedule. The protocol advises against using double doses or extra amounts of the medication to make up for a missed dose.


Q: Can Biocort cause changes in mood or behavior?

A: Biocort is a topical medication applied locally to the eye, meaning the systemic absorption into the body is generally minimal. For this reason, effects sometimes associated with high-dose oral or injectable steroids, such as changes in mood or behavior, are not commonly listed in the safety information for this topical eye product.


Q: Is Biocort safe to use for older adults (seniors)?

A: Regulatory documents indicate that no overall clinical differences in the safety or effectiveness of Biocort have been observed between older adults and other adult patients. Official labeling indicates that the standard adult regimen is generally used for the geriatric population.


Q: Are there different strengths or formulations of Biocort available?

A: Yes, Biocort is available in both an ophthalmic ointment and an ophthalmic suspension (eye drops) formulation. Official drug references also show that the suspension is available in different strengths, which contain varying concentrations of the dexamethasone component.


Q: How long does the effect of one dose of Biocort usually last?

A: Official dosing frequency, which is typically every four to six hours after the initial phase, is designed to maintain the drug’s intended action. This administration schedule described in official product information reflects the dosing interval required to maintain the drug’s therapeutic effect.


Q: Can Biocort affect fertility in men or women?

A: Studies on the component Tobramycin have not shown any evidence that it impairs fertility. Furthermore, general information for the Dexamethasone component used in eye drops suggests that it does not reduce fertility in men or women.


Q: Is it normal to have a slight headache when first using Biocort?

A: Headache is listed in some reports of adverse events for the product. However, it is not listed among the most frequent, common ocular side effects like redness or discomfort.


Q: Can Biocort cause problems with sleep?

A: Side effects involving sleep disturbance, such as insomnia, are mainly associated with the use of systemic corticosteroids (like pills or injections). These problems are typically not listed as common adverse reactions for this localized topical ophthalmic product.


Q: Is it possible to take Biocort while also using other topical treatments?

A: Official labeling advises against wearing soft contact lenses during use of the medication. The warning against wearing soft contact lenses, due to potential absorption of the preservative, is an example of a restriction on concurrent use with other topical devices.


Q: Why is Biocort sometimes called a 'systemic' treatment?

A: Biocort is officially classified as a topical ophthalmic medication, meaning it is applied locally and acts directly on the eye. While a minimal amount of the active ingredients may be absorbed into the body, regulatory documents define its primary route of administration and effect as localized, not systemic.


Q: Can Biocort cause changes in blood sugar levels?

A: The corticosteroid component (dexamethasone) is described in the label as potentially increasing blood glucose levels. This effect is the basis for the warning in official documents that people using anti-diabetic medications may need dosage adjustments.


Q: Is there a generic version of Biocort available?

A: Yes, official drug availability records confirm that a generic version of the ophthalmic suspension formulation containing dexamethasone and tobramycin has been approved and is available.


Q: Are Biocort and another drug, 'Bio-cort,' the same thing?

A: Official regulatory documents only define the composition of Biocort (dexamethasone/tobramycin). Phonetically similar names may refer to different pharmaceutical products, and Biocort’s official information does not mention or compare it to a product named 'Bio-cort.'


Q: Are there restrictions on who can use Biocort based on kidney or liver health?

A: While the active components are processed by the liver and kidneys, specific use restrictions or cautions based on pre-existing kidney or liver disease are not formally stated in the official label for this topical ophthalmic product.


Q: What kind of patient monitoring is needed when taking Biocort?

A: The official documents state that if the medication is used for 10 days or longer, the patient’s intraocular pressure (IOP) must be monitored. This is to manage the established risk of high eye pressure (glaucoma) associated with prolonged corticosteroid use.


Q: Are there any long-term side effects associated with Biocort use?

A: Official safety documents link prolonged use (typically 10 days or more) to specific duration-related risks. These risks include elevated Intraocular Pressure (IOP), the formation of a posterior subcapsular cataract, and an increased hazard of secondary infections in the eye.

How should Biocort be stored and disposed of?

How to Store and Dispose of Biocort

Official regulatory labeling dictates strict storage and handling requirements for Biocort (tobramycin/dexamethasone ophthalmic) to maintain its stability and effectiveness.


Storage Requirements

Condition Official Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep away from heat, moisture, and direct light.
Prohibition Keep from freezing.
Container Keep the container tightly closed and do not use if the tamper-evident seal is broken.
Handling The suspension bottle must be well shaken before use. Do not let the applicator tip touch any surface.

All medication must be kept out of the reach of children.


Disposal

Unused or expired Biocort should be disposed of via an authorized drug take-back program. If this is unavailable, the product should be mixed with an undesirable substance, placed in a sealed container, and put in the household trash. Do not flush the medication down a sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Biocort found in:

A-Z Index: